Virpax Pharmaceuticals, Inc.
VRPXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708331
Virpax Pharmaceuticals, Inc. was delisted in 2025; its insiders filed their last Form 4 on Jul 10, 2024; 12 institutions reported holding it in 13F filings for Q4 2024, worth $46.7K in total; no superinvestor held it.
13F holders, Q2 2023
Institutional positions in Virpax Pharmaceuticals, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −3 vs. Q1 2023
- Shares held
- 765.4K
- −347.7K (−31.2%) vs. Q1 2023
- Total value
- $827.7K
- −$46.1K (−5.3%) vs. Q1 2023
- New holders
- 1
- 1 more added
- Sold out
- 4
- 3 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRPX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 12 | $46.7K |
| Q3 2024 | 9 | $66.8K |
| Q2 2024 | 8 | $12.6K |
| Q1 2024 | 6 | $6.44K |
| Q4 2023 | 18 | $120.5K |
| Q3 2023 | 13 | $493.4K |
| Q2 2023 | 14 | $827.7K |
| Q1 2023 | 17 | $873.8K |
| Q4 2022 | 21 | $973.0K |
| Q3 2022 | 16 | $2.17M |
| Q2 2022 | 16 | $3.13M |
| Q1 2022 | 16 | $3.29M |
| Q4 2021 | 18 | $7.67M |
| Q3 2021 | 13 | $11.4M |
| Q2 2021 | 7 | $1.12M |
| Q1 2021 | 5 | $1.29M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Virpax Pharmaceuticals, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 400,000 | $432.0K | 1.55% | −301,455−43.0% | Reduced |
| The PNC Financial Services Group, Inc. | 100,875 | $108.9K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 89,354 | $97.0K | 0.00% | −5,946−6.2% | Reduced |
| Geode Capital Management, LLC | 66,038 | $72.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 65,145 | $70.4K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 15,221 | $16.4K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 11,953 | $12.9K | 0.00% | +11,953 | New |
| Quantum Private Wealth, LLC | 10,000 | $10.8K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,433 | $5.87K | 0.00% | −30−0.5% | Reduced |
| Advisor Group Holdings, Inc. | 600 | $648 | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 464 | $501 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 150 | $162 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 62 | $67 | 0.00% | +2+3.3% | Added |
| Hantz Financial Services, Inc. | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −19,045−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −17,012−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −16,070−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −123−100.0% | Sold out |